UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...
Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...
In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...
Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and ...
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback